Yong Tang

Yong Tang has worked in the field of biology since 1996. Yong began their career as a PhD Student at the Institute of Biophysics, Chinese Academy of Sciences, where they purified and characterized the first active earthworm fibrinolytic enzyme (EFEa) and determined its crystal structure. Following this, they were a Postdoc Fellow at the Dana-Farber Cancer Institute, where they engineered, expressed, and purified dozens of SKAP-Hom and SKAP55 proteins in various forms and crystallized and determined the structures of four proteins using heavy-atom SAD and MR phasing. In 2004, they became a Staff Scientist at The Wistar Institute, where they completed projects on p300 Yong'stone Acetyltransferase (HAT) drug discovery, Rtt109-Vps75 HAT complex structure-function correlation, and ASF1a-HIRA histone chaperone complex recognition. In 2012, they joined Constellation Pharmaceuticals as a Scientist II, where they completed 3 years of crystallographic support for the Constellation-Genentech collaboration on more than a dozen of bromodomains and was the recipient of the Constellation FIRST Award 2014. In 2015, they became a Senior Research Scientist I at the Broad Institute, where they worked on insect cell kinase proteins expressions, purifications, crystallography and characterizations via SEC-MALS, DSF, LC-MS and other techniques. In 2016, they were promoted to Senior Scientist and then Senior Scientist II at Relay Therapeutics, Inc. In 2020, they joined Recludix Pharma as a Senior Principal Scientist. In 2021, they were appointed Director of Structure Biology at Ensem Therapeutics.

Yong Tang obtained a B.S. in Cell Biology from Xiamen University between 1992 and 1996. Yong then went on to obtain a Ph.D. in Molecular Biophysics from the University of Chinese Academy of Sciences between 1996 and 2001.